PTC
PVLA

Private Trust Company’s Palvella Therapeutics PVLA Stock Holding History

Private Trust Company’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.23K Buy
50
+12
+32% +$1.25K ﹤0.01% 2136
2025
Q4 		$3.98K Sell
38
-13
-25% -$1.11K ﹤0.01% 2218
2025
Q3 		$3.2K Buy
+51
New +$2.27K ﹤0.01% 2266

Other funds holding PVLA

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Private Trust Company's PVLA Position: Q1 2026 in Review

Private Trust Company increased its Palvella Therapeutics (PVLA) stake by 32% in Q1 2026, buying an estimated $1.25K and bringing the position to 50 shares worth $6.23K. The position accounts for ﹤0.01% of the portfolio, ranked #2136.

Private Trust Company first reported a position in PVLA in Q3 2025 and has held it in 3 quarters since. 180 funds tracked by Wall St. Rank hold PVLA as of Q1 2026.

  • Private Trust Company held 50 shares of Palvella Therapeutics worth $6.23K as of Q1 2026.
  • Private Trust Company bought 12 Palvella Therapeutics shares in Q1 2026, an estimated $1.25K.
  • Palvella Therapeutics made up ﹤0.01% of Private Trust Company's portfolio in Q1 2026, its #2136 holding.
  • Private Trust Company first reported a position in Palvella Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 180 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q1 2026.

Based on Private Trust Company's 13F filing for Q1 2026, filed 30 Apr 2026.